Related Experiment Video
Updated: Jun 12, 2025

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Mycophenolate Mofetil as a Therapeutic Option in Refractory Immunoglobulin A Vasculitis: A Report of Two Atypical
Mohammed Al Towijry1, Muhanned Amawi1, Yassir M B1
1Pediatric Department, King Salman Armed Forces Hospital, Tabuk, SAU.
Abstract:
We report two rare and challenging cases of Immunoglobulin A (IgA) vasculitis with atypical clinical presentations, both of which responded favorably to treatment with corticosteroids and mycophenolate mofetil (MMF). The first case involved a patient with pulmonary-renal syndrome, a rare manifestation of IgA vasculitis. The second case presented predominantly with severe gastrointestinal manifestations and was refractory to conventional therapies, including high-dose corticosteroids, intravenous immunoglobulin (IVIG), and cryoprecipitate. In both cases, the introduction of MMF alongside corticosteroids resulted in significant clinical improvement and eventual remission. These cases underscore the potential role of MMF as an adjunctive therapy in managing severe or refractory forms of IgA vasculitis, particularly when standard treatment options prove insufficient.
More Related Videos
10:35Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Myocarditis III: Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Immunotherapy